Edition:
India

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

63.25CHF
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
CHF63.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
43,276
52-wk High
CHF84.10
52-wk Low
CHF62.60

Summary

Name Age Since Current Position

Domenico Scala

53 2016 Chairman of the Board of Directors

David Veitch

50 2018 Chief Executive Officer, Member of the Management Committee

Donato Spota

2013 Member of the Management Committee, Chief Financial Officer

Gerrit Hauck

2018 Chief Technology Officer

Laurenz Kellenberger

2009 Member of the Management Committee, Chief Scientific Officer

Marc Engelhardt

2018 Member of the Management, Chief Medical Officer

Anne Stehlin

2018 Member of the Management Board, Head of Global Quality Management

Alf Nicklasson

63 2016 Member of the Board of Directors

Nicole Onetto

64 2017 Member of the Board of Directors

Steven Skolsky

62 2011 Member of the Board of Directors

Thomas Werner

62 2011 Member of the Board of Directors

Peer Schroeder

2016 Head of Corporate Communications & Investor Relations

Biographies

Name Description

Domenico Scala

Mr. Domenico Scala has served as Chairman of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. He is Chairman of the Audit Committee at the Company. Prior to that, he was Vice Chairman of the Board of Directors at the Company from April 9, 2013. Previously, he was Member of the Board of Directors at the Company from April 6, 2011. From 2007 to 2011, Mr. Scala was President and Chief Executive Officer of Nobel Biocare Holding AG and from 2003 to 2007, he was Chief Financial Officer of Syngenta International AG. From 1995 to 2003, he served in various senior leadership positions at Roche Holding AG. Prior to that, he served as Finance Director with Panalpina Italy Spa and Senior Auditor with Nestle SA. Mr. Scala was elected as a Member of the Bank Council of the Basler Kantonalbank in December 2016 (term starting on April 1, 2017). In addition, Mr. Scala has been President of BaselArea, Chairman of the Board of Directors of BAK Basel Economics AG and a Member of the Board of Overseers of Tufts University in Boston, Massachusetts. From May 2012 until May 2016, Mr. Scala was Chairman of the Audit and Compliance Committee of FIFA (Federation Internationale de Football Association). Mr. Scala graduated from the University of Basel with a degree in economics and holds Executive Development degrees from INSEAD and London Business School.

David Veitch

Mr. David Veitch has been appointed Chief Executive Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd effective as of April 19, 2018. He has served as Chief Commercial Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd since September 1, 2014. Mr. Veitch served as the President of European Operations at Savient Pharmaceuticals from 2012 to 2013. From 2007 to 2011, he served as Senior Vice President of European Marketing & Brand Commercialization at Bristol-Myers Squibb Pharmaceuticals. From 2004 to 2007, he was Vice President and General Manager UK at Bristol- Myers Squibb Pharmaceuticals. Prior to this Mr. Veitch held various general management and commercial roles in Bristol-Myers Squibb Pharmaceuticals and prior to that with SmithKline Beecham Pharmaceuticals. Mr. Veitch received a B.Sc. in Biology from the University of Bristol.

Donato Spota

Mr. Donato Spota has served as Member of the Management Committee and Chief Financial Officer of Basilea Pharmaceutica Ltd since November 2013. Mr. Spota has held various positions at Basilea since joining the company in 2002, including Global Head of Finance & Services and Head of Global Controlling. Prior to joining Basilea, Mr. Spota held positions in financial planning and controlling at F. Hoffmann-La Roche, Basel, in the area of Pharma Global Informatics. Mr. Spota has a degree in Information Technology from the Swiss BBT (Bundesamt fuer Berufsbildung und Technologie) and holds a Master degree in business administration from the University of Applied Sciences Nuertingen (Germany).

Gerrit Hauck

Dr. Gerrit Hauck is Chief Technology Officer of the Company. Dr. Hauck joins Basilea from Sanofi, where he was Cluster Head Synthetic Molecules. In this role he was overseeing most of the company's technical development programs for synthetic molecules from pre-clinical candidates to launch. At the same time he was a member of Sanofi's Research Stage Gate Committee, which is responsible for the transition of candidate molecules from research into development. He also brings significant experience in implementing strategic projects with contract manufacturing organizations. Dr. Hauck graduated as a pharmacist from the University of Heidelberg, Germany and holds a PhD from Saarland University, Germany.

Laurenz Kellenberger

Dr. Laurenz Kellenberger, Ph.D., has been Member of the Management Committee and Chief Scientific Officer of Basilea Pharmaceutica Ltd since January 27, 2009. From 2000 to 2009, he held roles of increasing responsibility at Basilea and served as Head of Chemistry from 2004 to 2009 and member of the research management team with responsibilities for key projects from lead finding and optimization through to preclinical development. He holds a Ph.D. in Organic Chemistry from the Swiss Federal Institute of Technology Zurich (ETH Zürich). After receiving his Ph.D., he continued his scientific research at the University of Cambridge (UK) and at F. Hoffmann-La Roche, Basel, where he held different positions in preclinical research and chemical technologies before joining Basilea in 2000. He is author of numerous scientific publications.

Marc Engelhardt

Dr. Marc Engelhardt has been Member of the Management Committee and Chief Medical Officer of Basilea Pharmaceutica Ltd since January 1, 2018. He joined Basilea in 2010 as Head of Clinical Research. In 2012, he was promoted to Head of Development. In this role Dr. Engelhardt led Basilea's clinical research and development group. Prior to joining Basilea, Dr. Engelhardt served as Global Program Medical Director at Novartis Pharma AG in Basel, before which he held various positions with increasing responsibility at Bracco-Altana, Konstanz, Germany and Bracco Diagnostics in Princeton, NJ, USA. Dr. Engelhardt holds a medical degree and a Ph.D. from the University Frankfurt/ Main, Germany and is board certified in internal medicine.

Anne Stehlin

Alf Nicklasson

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D., has been Member of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. Prior to that, he was Chairman of the Board of Directors of the Company from 2013. He is Chairman of the Compensation Committee and Member of the Audit Committee at the Company. Dr. Nicklasson is a Honorary Associate Professor at the Pharmaceutical Faculty, University of Uppsala (Sweden) since 1985. From 2007 to 2010, Dr. Nicklasson served as president and chief executive officer of Biovitrum AB and Swedish Orphan Biovitrum AB. From 1999 to 2007 he held various executive vice president positions at AstraZeneca Plc., and acted as a member of the Executive Committee. Dr. Nicklasson is member of the board of Biocrine AB (Sweden) and chairman of the board of directors of Kymab Group Ltd. (UK), Orexo AB (Sweden) and Zealand Pharma A/S (Denmark). He also serves as a consultant at Excore Consulting KB in Sweden. Dr. Nicklasson is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the University of Uppsala.

Nicole Onetto

Dr. Nicole Onetto, M.D., has been Member of the Board of Directors of Basilea Pharmaceutica Ltd since April 27, 2017. She is Member of the Corporate Governance Committee at the Company. She is currently an independent consultant in oncology, drug development and translational research. From 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada. From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc. Between 2002 and 2005, she served at OSI Pharmaceuticals, Inc., first as Executive Vice President-Oncology, and then as Chief Medical Officer and Executive Vice President. Previously she served in senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc. She is currently on the board of Sierra Oncology, Inc., a Vancouverbased oncology hematology company, on the board of NBE-Therapeutics AG, a Basel based biotechnology company, and previously served from 2005 to 2016 as a member of the board of ImmunoGen Inc. She obtained her MD from the University of Paris and holds a Master of Pharmacology from the University of Montréal.

Steven Skolsky

Mr. Steven D. Skolsky has served as Member of the Board of Directors at Basilea Pharmaceutica Ltd. since April 6, 2011. Prior to that, he served as Vice Chairman of the Board of Directors of the Company from April 29, 2009. He has served as Member of the Board of Directors from March 19, 2008 until April 29, 2009. He is Member of the Compensation Committee at the Company. From 2011 until August 2016, Mr. Skolsky served as a Senior Executive at Quintiles Transnational Holdings in various positions, most recently as Senior Vice President and Managing Director and previously, Head of Global Clinical Operations. From 2006 to 2011, Mr. Skolsky served as Chief Executive Officer and President of Sequoia Pharmaceuticals Inc. and from 2004 to 2006 as Chief Executive Officer of Trimeris Inc. Mr. Skolsky joined Trimeris from GlaxoSmithKline (GSK), where he had served for more than 20 years in a range of senior leadership roles, including Senior Vice President, Global Product Strategy and Clinical Development, and Managing Director of GSK’s operations in Australia and New Zealand. Mr. Skolsky serves on the Foundation Board of the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill (USA). Mr. Skolsky holds a B.A. in Biology from the University of North Carolina at Chapel Hill.

Thomas Werner

Dr. Thomas Werner has served as Member of the Board of Directors at Basilea Pharmaceutica Ltd since November 29, 2011. He is Member of the Compensation Committee at the Company. Dr. Werner served as Senior Vice President and Managing Director of GlaxoSmithKline Germany from 2001 to 2008. From 1997 to 2000, he served as Managing Director for Glaxo Wellcome Germany and Director of the Central European Region. Dr. Werner has also worked at Bristol- Myers Squibb Germany and Convatec Germany/ Central Europe. Dr. Werner is Member of the Boards of Vectura Group plc and BSN Medical GmbH and is Member of the Advisory Board of Riemser Pharma GmbH. He also serves as the Chairman of the investment advisory committee of the Health for Life Capital fund of Seventure Partners (France). He holds a Ph.D. in Chemistry from Georg-August-Universitaet Goettingen.

Peer Schroeder